# Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

> **NCT06854224** · PHASE2 · RECRUITING · sponsor: **Marianne Goodman** · enrollment: 30 (estimated)

## Conditions studied

- Suicide Risk
- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Suvorexant (dual orexin receptor antagonist)

## Key facts

- **NCT ID:** NCT06854224
- **Lead sponsor:** Marianne Goodman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06854224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06854224, "Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06854224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*